{"id":"W4416391612","doi":"10.1016/j.annonc.2025.09.103","title":"LBA87 EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; SAIT Polytechnic; University of British Columbia","funders":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Astellas Pharma; Bristol-Myers Squibb; AstraZeneca; Movember Foundation; University of California, San Francisco; Comprehensive Cancer Center, City of Hope; Exelixis; Memorial Sloan-Kettering Cancer Center; Vanderbilt University; NorthShore University HealthSystem; Genentech; University of Pittsburgh; University of Texas MD Anderson Cancer Center; Pfizer; Cancer Institute, University of Pittsburgh; Roswell Park Cancer Institute","keywords":"Enzalutamide; Overall survival; Prostate cancer; Recurrent prostate cancer; Survival analysis; Progression-free survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007117637,0.0003294509,0.001067808,0.0003633087,0.000197488,0.0008050021,0.0003993971,0.0003668843,0.003664356],"category_scores_gemma":[0.000804611,0.0001180603,0.0008753739,0.0004068972,0.0002686372,0.0006477136,0.000378607,0.001219074,0.0006032288],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007958717,"about_ca_system_score_gemma":0.0009559235,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003070435,"about_ca_topic_score_gemma":0.01188418,"domain_scores_codex":[0.999656,0.0001248052,0.00002034487,0.00003275793,0.00005491575,0.0001111946],"domain_scores_gemma":[0.9996636,0.00006949328,0.00005990534,0.00002704748,0.00002272439,0.0001572148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1802999,0.005808342,0.06032444,0.0009172611,0.003011366,0.0005397612,0.0001922916,0.00657301,0.01657302,0.00109318,0.01430675,0.7103606],"study_design_scores_gemma":[0.02893645,0.1949988,0.6986781,0.0005589804,0.00698589,0.00201793,0.0007013801,0.008523243,0.01539679,0.002345005,0.04068743,0.0001699786],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.978323,0.01118587,0.0002334013,0.001137784,0.0001750786,0.00006217466,0.001030029,0.0001324337,0.007720251],"genre_scores_gemma":[0.9926524,0.002465298,0.0002035648,0.0003829185,0.00009930746,0.00003521438,0.001253386,0.00002793631,0.002880056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003664356,"threshold_uncertainty_score":0.01225847,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06934023701720003,"score_gpt":0.4391255060900267,"score_spread":0.3697852690728267,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}